NanoRepro AGXTER:NN6 +12.79%51 Current Ratio is 32.15 as of Jun. 2025, which is 63% above its 10-year median of 19.75. GuruFocus rates XTER:NN6 with a GF Score™ of 51/100 and a GF Value™ of €1.00 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, NanoRepro AG ranks better than 99.07% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. NanoRepro AG's current ratio for the quarter that ended in Jun. 2025 was 32.15.
NanoRepro AG has a current ratio of 32.15. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for NanoRepro AG's Current Ratio or its related term are showing as below:
XTER:NN6'
s Current Ratio Range Over the Past 10 Years
Min: 4.8 Med: 19.75 Max: 74.49
Current: 32.15
During the past 13 years, NanoRepro AG's highest Current Ratio was 74.49. The lowest was 4.80. And the median was 19.75.
XTER:NN6's Current Ratio is ranked better than 99.07% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs XTER:NN6: 32.15
NanoRepro AG (XTER:NN6) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
NanoRepro AG Current Ratio Related Terms
NanoRepro AG Current Ratio Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:NN6 vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, NanoRepro AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NanoRepro AG (XTER:NN6) has a Current Ratio of 32.15 as of Jun. 2025. This is 63% above median its historical median of 19.75. Over the past decade, NanoRepro AG's Current Ratio has ranged from 4.80 to 74.49. According to the industry distribution chart, NanoRepro AG ranks #2 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 0.90000000000001%.
Is NanoRepro AG's Current Ratio too high?
NanoRepro AG's current Current Ratio of 32.15 is 63% above median its 10-year median of 19.75. Over the past 10 years, this metric has ranged from a low of 4.80 to a high of 74.49. The Medical Diagnostics & Research industry median Current Ratio is 2.10. NanoRepro AG's value of 32.15 is 1431% above this industry median. Based on the distribution chart, NanoRepro AG ranks #2 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, NanoRepro AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #2 out of 215 companies for Current Ratio. This places NanoRepro AG in the top 1% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.10. NanoRepro AG's value of 32.15 is 1431% above this benchmark. Historically, NanoRepro AG's own Current Ratio has ranged from 4.80 to 74.49 over the past decade. While the company's 10-year median is 19.75 vs. the industry median of 2.10, NanoRepro AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NanoRepro AG's current Current Ratio of 32.15 is 1431% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current Current Ratio is 32.15, which is 63% above median its own 10-year median of 19.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.00, compared to a current price of €2.16 — trading 116% above its estimated fair value. The current Current Ratio is 32.15, which is 63% above median its 10-year median of 19.75 and 1431% above the Medical Diagnostics & Research industry median of 2.10. NanoRepro AG's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current Current Ratio is 32.15 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (XTER:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.16 is trading 116% above its estimated GF Value™ of €1.00.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for XTER:NN6:
Current Ratio: 32.15 (63% above median its 10-year median of 19.75)
GF Value™: €1.00 vs. price of €2.16 (116% above fair value)
Industry Position: 1431% above the Medical Diagnostics & Research median (#2 of 215)
No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
51GF Score
Get the complete analysis for XTER:NN6
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:NN6 has been successfully added to your 
